Literature DB >> 17203291

Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra.

L B Moran1, E Croisier, D C Duke, M E Kalaitzakis, F Roncaroli, M Deprez, D T Dexter, R K B Pearce, M B Graeber.   

Abstract

The identification of mutations that cause familial Parkinson's disease (PD) provides a framework for studies into pathways that may be perturbed also in the far more common, non-familial form of the disorder. Following this hypothesis, we have examined the gene regulatory network that links alpha-synuclein and parkin pathways with dopamine metabolism in neuropathologically verified cases of sporadic PD. By means of an in silico approach using a database of eukaryotic molecular interactions and a whole genome transcriptome dataset validated by qRT-PCR and histological methods, we found parkin and functionally associated genes to be up-regulated in the lateral substantia nigra (SN). In contrast, alpha-synuclein and ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) gene expression levels were significantly reduced in both the lateral and medial SN in PD. Gene expression for Septin 4, a member of the GTP-binding protein family involved in alpha-synuclein metabolism was elevated in the lateral parkinsonian SN. Additionally, catalase and mitogen-activated protein kinase 8 and poly(ADP-ribose) polymerase family member 1 (PARP1) known to function in DNA repair and cell death induction, all members of the dopamine synthesis pathway, were up-regulated in the lateral SN. In contrast, two additional PD-linked genes, glucocerebrosidase and nuclear receptor subfamily 4, group A, member 2 (NR4A2) showed reduced expression. We show that in sporadic PD, parkin, alpha-synuclein and dopamine pathways are co-deregulated. Alpha-synuclein is a member of all three gene regulatory networks. Our analysis results support the view that alpha-synuclein has a central role in the familial as well as the non-familial form of the disease and provide steps towards a pathway definition of PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17203291     DOI: 10.1007/s00401-006-0181-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  19 in total

Review 1.  NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.

Authors:  Mickael Decressac; Nikolaos Volakakis; Anders Björklund; Thomas Perlmann
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

2.  Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration.

Authors:  Zachary A Sorrentino; Yuxing Xia; Cory Funk; Cara J Riffe; Nicola J Rutherford; Carolina Ceballos Diaz; Amanda N Sacino; Nathan D Price; Todd E Golde; Benoit I Giasson; Paramita Chakrabarty
Journal:  Neurobiol Dis       Date:  2018-09-06       Impact factor: 5.996

Review 3.  Nurr1-Based Therapies for Parkinson's Disease.

Authors:  Jie Dong; Song Li; Jing-Lin Mo; Huai-Bin Cai; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2016-03-25       Impact factor: 5.243

Review 4.  Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression.

Authors:  Jaclyn Nicole Le Grand; Laura Gonzalez-Cano; Maria Angeliki Pavlou; Jens C Schwamborn
Journal:  Cell Mol Life Sci       Date:  2014-11-18       Impact factor: 9.261

5.  Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite.

Authors:  John M Bruning; Yan Wang; Francesca Oltrabella; Boxue Tian; Svetlana A Kholodar; Harrison Liu; Paulomi Bhattacharya; Su Guo; James M Holton; Robert J Fletterick; Matthew P Jacobson; Pamela M England
Journal:  Cell Chem Biol       Date:  2019-03-07       Impact factor: 8.116

6.  Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress.

Authors:  L Bouman; A Schlierf; A K Lutz; J Shan; A Deinlein; J Kast; Z Galehdar; V Palmisano; N Patenge; D Berg; T Gasser; R Augustin; D Trümbach; I Irrcher; D S Park; W Wurst; M S Kilberg; J Tatzelt; K F Winklhofer
Journal:  Cell Death Differ       Date:  2010-11-26       Impact factor: 15.828

7.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Laurel Macey; Lauren T Brown; Anna M Krichevsky; Susan L Andersen; Robert M Stephens; Francine M Benes; Kai C Sonntag
Journal:  Brain       Date:  2008-12-03       Impact factor: 13.501

8.  Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Robert Stephens; Kai C Sonntag
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

9.  Stable isotope labeling and label-free proteomics of Drosophila parkin null mutants.

Authors:  Zhiyin Xun; Thomas C Kaufman; David E Clemmer
Journal:  J Proteome Res       Date:  2009-10       Impact factor: 4.466

10.  Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression.

Authors:  Nikolaos Volakakis; Katarina Tiklova; Mickael Decressac; Maria Papathanou; Bengt Mattsson; Linda Gillberg; André Nobre; Anders Björklund; Thomas Perlmann
Journal:  J Neurosci       Date:  2015-10-21       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.